OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2
- 2.6k Downloads
Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the activity of lapatinib via combination with other therapies.
In the present studies, estrogen receptor (ER) positive and ER negative breast cancer cells were genetically manipulated to up- or downregulate eIF2-alpha, its phospho-mutant, Nck1, or Nck2, then treated with OSU-03012, lapatinib or the combination and assayed for cytotoxicity/cytostaticity using clonogenic assays.
Treatment of breast cancer cell lines with lapatinib and OSU-03012 (a small molecule derivative of the Cox-2 inhibitor celecoxib) induced synergistic cytotoxic/cytostatic effects. This combination therapy corresponded to an increase in the phosphorylation of eIF2-α at serine51 and a decrease in Nck1 expression. Ectopic expression of phospho-mutant eIF2-α (Ser51Ala) or downregulation of eIF2-α in addition to downregulation of the eIF2-α kinase PERK inhibited the synergistic and cytotoxic effects. Furthermore, ectopic expression of Nck1, but not Nck2 abolished the decrease in cell viability observed in combination-treated cells. Downregulation of Nck1 failed to “rescue” the ablation of the cytotoxic/cytostatic effects by the phospho-mutant of eIF2-α (Ser51Ala) demonstrating that Nck1 downregulation is upstream of eIF2-α phosphorylation in the anti-survival pathway activated by lapatinib and OSU-03012 treatment. Finally, co-immunoprecipitation assays indicated that eIF2-α dissociates from the Nck1/PP1 complex after OSU-03012 and lapatinib co-treatment.
These data indicate that OSU-03012 and lapatinib co-treatment is an effective combination therapy, which functions to enhance cell killing through the Nck1/eIF2 complex. Hence, this complex is a novel target for the treatment of metastatic breast cancer.
KeywordsBreast cancer Lapatinib Combination therapy Nck eIF2-alpha
Avian erythroblastosis oncogene B
Eukaryotic initiation factor
Protein kinase R
PKR-like ER kinase
Death receptor 5
Phosphatase and tensin homolog
Phosphate buffered saline
Fetal bovine serum
Breast cancer is currently the second most common cause of death due to cancer among women and leads to approximately 8,000 to 10,000 deaths per year . Metastasis is the main cause of breast cancer related deaths, and these metastases are only poorly controlled with first generation therapies such as taxanes [2, 3, 4]. Both the ErbB2 and the ErbB1 receptors, members of the epidermal growth factor receptor (EGFR) family, are upregulated in many types of cancer, and overexpression of these proteins is associated with a greater likelihood of metastasis. Hence, this receptor family is a current therapeutic target for the treatment of metastatic breast cancer.
The epidermal growth factor receptor family comprises four members known as EGFR (ErbB1), Her2 (ErbB2), ErbB3, and ErbB4. Homo- and hetero-dimerization of these tyrosine kinase receptors occurs as a result of binding by various growth factors such as epidermal growth factor (EGF), after which cytoplasmic tail tyrosine residues are phosphorylated [5, 6]. Phosphorylation leads downstream to the activation of various signaling cascades such as the extracellular-regulated kinase (ERK), and the Akt kinase cascades. These cascades lead to propagation of both survival and death signals [7, 8]. Recently, lapatinib (Tykerb, GSK), an ErbB1/2 inhibitor, was approved for the treatment of metastatic breast cancer, as lapatinib is implicated in better outcomes in patients with metastases. Unfortunately, outcomes are still not ideal for patients with metastatic disease [9, 10]. Thus therapies which enhance lapatinib-induced cell killing are needed in the clinic.
One possibility for combination therapy with lapatinib is the small molecule inhibitor, OSU-03012. This novel Celecoxib derivative induces death in cancer cells from multiple lineages without inhibiting Cox-2 [11, 12, 13, 14]. Previous analyses indicate that OSU-03012 induces cell death partially via the activation of ER stress proteins including PKR-like ER kinase (PERK). PERK is a direct kinase of the eukaryotic initation factor 2 (eIF2) and phosphorylates this protein at the serine51 residue of the alpha subunit [15, 16]. Phosphorylation of eIF2-α leads to increased expression of the pro-apoptotic transcription factor CHOP as well as the expression of HSP70 family chaperones. Our previous analyses demonstrated that OSU-03012 reduced Grp78/BiP levels and increased HSP70 levels in a PERK-dependent fashion [11, 12]. The laboratory of Dr. Chen, in general agreement with our previous studies, has shown that inhibition of ErbB1 in ErbB1-addicted NSCLC enhances the toxic effects of OSU-03012, and that this is in part due to increased ER stress signaling and increased levels of DR5 . The laboratory of Dr. Paul Dent has also recently published that OSU-03012 and lapatinib synergize in glioblastoma cell lines, although by a different mechanism than the one found in this manuscript .
In the current studies, we assessed whether OSU-03012-induced killing of breast cancer cell lines was enhanced by the addition of lapatinib. We show that a decrease in adaptor protein Nck1, but not Nck2, [18, 19] is necessary for cell killing in both ER positive and ER negative breast cancer cell lines. Furthermore, we show that increased eIF2-α phosphorylation on Serine51 induced by the combination of OSU-03012 and lapatinib is responsible for the synergistic effects of these agents. Thus, the Nck1/eIF2 complex is identified in this study as a novel target for the treatment of metastatic breast cancer.
The MDA-MB-231 cell line (purchased from American Type Culture Collection, ATCC) and the BT474 cell line (ATCC) were maintained in RPMI (Invitrogen). ATCC published standards are recognized by the American National Standards Institute (ANSI) and are compatible with the requirements of the International Organization for Standardization (ISO). Both cell lines were supplemented with 10% fetal bovine serum (FBS, Invitrogen) and 1% Penicillin / Streptomycin (Invitrogen). All cell lines were maintained in a 95% air / 5% CO2 incubator at 37°C. Cells were passaged once every 3-5 days (~90% confluence), and all experiments were performed during the first 12 passages.
Plasmids and reagents
eIF2-α expression plasmids were constructed by Ron et. al. and purchased from Addgene (plasmid numbers #21808 and 21807, ). GFP-tagged Nck1 and Nck2 plasmids were a generous gift from Dr. L. Larose [18, 19]. Antibodies to Nck1, phospho-eIF2-α (Serine51), total eIF2-α, ERK, phospho-ERK, PTEN, phospho-PTEN, PP1, phospho-PP1 and β-actin were purchased from Cell Signaling Technologies. Nck2 antibodies were purchased from Novus Biologicals. siRNA molecules against Nck1 and mutant siRNA molecules were custom manufactured by Dharmacon. The sequence used was previously published by Dr. W. Li and colleagues . A mutant sequence containing 9 mutations was also manufactured as a control to ensure specificity of knockdown. Sequences are as follows (single stranded, sense): siNck1 5’ GGC CTT CAC TCA CTG GAA A 3’; Mutant Nck1 5’ CGC TTC CAC TGC TGA GAG A 3’. Pre-designed and validated siRNA molecules to downregulate eIF2-α and control scrambled siRNA molecules were purchased from Qiagen. siRNAs targeting ATF6 and IRE-1 were generous gifts from the laboratory of Dr. Paul Dent.
Cells were treated as indicated. 24 - 48 hrs later, cells were trypsinized, washed and stained with Annexin V-PE and propidium iodide using the ApoScreen Annexin V Apoptosis Kit (Southern Biotech) according to manufacturer’s instructions. Cells were detected using a BD FACSCanto II and analyzed using the accompanying FACSDIVA software.
Plasmid transfections were accomplished using the Effectene system (Qiagen) according to manufacturer’s instructions. Briefly, plasmid DNA (1 μg) was incubated in the presence of EC buffer and a 150:18 dilution of the Enhancer reagent for 10 minutes followed by the addition of the Effectene reagent (at a 168:20 dilution). Plasmid samples were incubated for a further 10 minutes then diluted to 1 mL with complete medium and added by single drops to the sample. Cells were allowed to accumulate the recombinant proteins for 24-48 hours. All steps excluding the incubation of DNA, EC buffer, Enhancer reagent and Effectene reagent were undertaken in 10% FBS-containing medium.
siRNA transfections were performed using the Dharmafect 1 reagent (Dharmacon) according to manufacturer’s instructions. Briefly, siRNA molecules (25 nM final concentration) were incubated in serum- and antibiotic-free medium. Concurrently, 5 μL Dharmafect 1 reagent was incubated in serum- and antibiotic-free medium. Both tubes were incubated at room temperature for 10 minutes then combined and incubated at room temperature for an additional 20 minutes. siRNA was then added to cells one drop at a time. Cells were incubated for at least 48 hours to achieve downregulation of the target mRNA.
Clonogenic assays were performed as previously described . Briefly, cells were transfected and treated as indicated in the figure legends. Cells were then plated onto 6-well plates at a density of 200-400 cells / well and allowed to form colonies over the next 10-14 days. Colonies were stained using crystal violet stain, and cells that underwent ≥ 50 doublings were counted as a colony.
Cells were plated, cultured and treated as indicated. Cells were washed 2 times in PBS and lysed using CelLytic (Sigma) lysis buffer supplemented 1:100 with protease and phosphatase inhibitors (Cell Signaling) and by sonication. Protein concentration was assessed using Bio-Rad protein assay reagent. Equal amounts (10-20 μg) of protein were subsequently electrophoresed on 10-12% SDS polyacrylamide gels and electrophoretically transferred to PVDF membranes (Bio-Rad). Membranes were blocked in PBS supplemented with 0.1% TWEEN-20 and 5% dry milk and exposed to primary and secondary antibodies as indicated. Membranes were developed using SuperSignal West reagents (Pierce).
Cells were treated as described in figure legends. Cells were then harvested using NP-40 buffer (20 mM Tris-HCl, pH 8.0; 137 mM NaCl; 2 mM EDTA; 2% NP-40; protease and phosphatase inhibitor cocktail (added prior to use)). Lysate was pre-incubated with protein A/G agarose beads (1 h, 4°C with rotation). Concurrently, Protein A/G agarose beads (Pierce) were incubated with antibodies raised against either total eIF2-α or total PP1 (Cell Signaling). Beads were washed 3 times with NP-40 buffer and then added to cell lysates. Lysates + beads were incubated at 4°C for 4 – 16 h with rotation and washed 3 times in NP-40 buffer. Bound proteins were released from the antibody-coated beads using 200 mM glycine, pH 3.0. Electrophoresis and western blotting procedures were then performed as previously described.
Isobologram analyses were performed using the method of Chou and Talalay . Briefly, colony formation assays were performed using stepwise increasing concentrations of OSU-03012 and lapatinib either singly or in combination (1 μM, 2 μM and 3 μM both in single and in combination treatments). Analyses were then performed using the Calcusyn program (Biosoft). Fraction affected (FA) was calculated and the combination index (CI) was then used as a measure of synergy.
All P values refer to paired student’s t-tests; differences with p≤0.05 were considered significant. Analyses were performed using the Sigmaplot software.
Results and discussion
Isobologram analysis of MDA-MB-231 and BT474 cell lines indicates that the drugs are synergistic in multiple breast cancer lines
Drug Conc lap
Drug Conc. OSU
Interestingly, OSU-03012 and lapatinib combination therapy was more effective against MDA-MB-231 cells than BT474 cells. Therefore, our findings argue that targeting ER stress proteins may increase the efficacy of traditional therapies specifically for metastatic breast cancers [11, 12, 13] since the BT474 cell line is less invasive than the triple negative MDA-MB-231 cell line [25, 26]. Specifically, we found a greater decrease in cell viability and a lower CI value for synergy between OSU-03012 and lapatinib in the triple negative cell line MDA-MB-231 (harvested from the metastatic pleural ascites) than in ErbB2-amplified BT474 cell line (harvested from a primary site). These findings provide support for the hypothesis that OSU-03012 and lapatinib in combination may be more effective against metastatic breast cancers than non-metastatic breast cancers. These results are also in line with recent studies by Sanz-Pamplona et. al., which showed that upregulation of GRP94, an ER stress protein, is an effective marker for brain metastases of breast cancers , and others , which showed that other ER stress markers are upregulated during suspension conditions.
Our data demonstrating that MDA-MB-231 cells are more sensitive to the combination of OSU-03012/lapatinib are also in general agreement with the findings in Figure 7B, that PP1 associates significantly less with eIF2-α after OSU/lapatinib treatment in MDA-MB-231 cells than in BT474 cells. While PTEN, Raf, and Akt levels and mutation status appear to be similar in both MDA-MB-231 and BT474 cells [29, 30, 31], BT474 cells express a constitutively active form of PI3KCA (K111N), in addition to overexpressing ErbB2 . It may be that upregulation of the PI3K/Akt pathway represents a potential pathway of resistance for cell lines treated with OSU-03012/lapatinib in combination. Therefore, inhibitors of the PI3K pathway should be combined with OSU-03012/lapatinib in future studies.
PTEN  and protein phosphatase 1 (PP1, ) are two phosphatases whose activities are linked to eIF2-α phosphorylation. Thus, we assessed the activity of these phosphatases as upstream determinants of OSU-03012/lapatinib-induced eIF2-α phosphorylation. First, the phospho-status of PTEN was examined as an indicator of activation, but no increases were observed for the phosphorylation of PTEN (Figure 4E). Instead, the phosphorylation pattern was similar to the pattern of total PTEN expression. Hence, enhanced PTEN activity is unlikely affecting OSU-03012- and lapatinib-induced cell death/reduced survival. In Figure 4E, we observed that the phosphorylation of the PP1 was significantly increased indicating a decrease in the activity of PP1 (Figure 4E, ). Thus, with regards to upstream events leading to eIF2-α activation, PP1, but not PTEN, is a likely candidate responsible for the dephosphorylation of eIF2-α induced by OSU-03012/lapatinib in combination.
Taken together, the data in Figures 3 and 4 showed that OSU-03012/lapatinib in combination upregulated ER stress-related pathways, and that downregulation of eIF2-α phosphorylation at serine51 completely ablated cell death induced by OSU-03012/lapatinib and demonstrated that PP1 was a likely candidate for eIF2-α dephosphorylation.
ER stress aggravators (ERSAs) are a relatively recent addition to our arsenal of therapeutic agents for the treatment of cancer. There are multiple reports [27, 28, 35] that ER stress factors are upregulated in many types of cancer suggesting that these pathways may be ones to which cancers may become addicted and therefore represent good targets for treatment. OSU-03012 represents one ERSA which may be used to enhance ER stress pathways in cancer cells. This may activate a response in which the cancer cell shifts from using ER stress signaling as a survival mechanism to an apoptotic one. Our findings demonstrate that eIF2-α phosphorylation is a major event in the cell death pathways induced during treatment with OSU-03012/lapatinib. Furthermore, the question whether other molecules that induce ER stress will also enhance lapatinib-induced cell killing should be pursued in light of these studies.
Nck1, but not Nck2 is intrinsic to OSU-03012/lapatinib-induced cell death
Larose and colleagues [18, 19] found that Nck1 forms a complex with eIF2 and PP1. Dissociation of this complex can lead to eIF2-α phosphorylation at serine51 and a decrease in protein translation. eIF2-α may also be phosphorylated at serine51 by the ER resident kinase PERK during ER stress. Since we show in Figure 2 that OSU-03012/lapatinib in combination induces ER stress in part by PERK activation, we performed studies aimed at determining the role of Nck1 in ER stress-induced cell death by OSU-03012 and lapatinib in combination. Our studies showed that ectopic expression of Nck1 abolished the cell death induced by OSU-03012/lapatinib. Furthermore, upregulation of Nck1 “rescues” the cell death induced by wild-type eIF2-α overexpression. Thus, the studies reported here demonstrate that the Nck1/eIF2 complex is a key point at which lapatinib and OSU-03012 act to synergistically kill metastatic breast cancer cells, and generally support Larose’s findings that PP1 is important in this complex.
In contrast to our findings implicating a PP1, Nck1 and eIF2-containing complex in the cytotoxicity/cytostaticity induced by OSU-03012/lapatinib, the Dent laboratory has recently published that lapatinib enhances OSU-03012-induced cell killing in glioblastoma models and that this phenomenon occurs via an ErbB/Akt/PTEN pathway . MDA-MB-231 and BT474 cells as well as GBM6 and GBM12 (used in ) cell lines are all PTEN wild-type. Therefore, cancer-type-specific pathways may be responsible for this apparent contradiction. Our data suggest that further experiments may need to take these cancer-specific differences into account when designing therapeutic regimens.
Recently, EGFR-mediated Nck1/Rap1 activation has been shown to upregulate metastasis in a model of metastatic pancreatic carcinoma without affecting primary tumor growth . These findings raise two intriguing possibilities: 1) Nck1 downregulation may be a singularly efficacious inducer of cell death specifically for metastatic breast cancer cells, and 2) eIF2 may play a role in the metastatic process. We observe a small, but insignificant decrease in the viability of BT474 cells (a non-invasive cell line, see Figure 7) after RNAi-mediated inhibition of Nck1, which may be indicative that inhibition of Nck1 alone may induce cell death in more invasive cell lines. In addition, we observe that Nck1 is downregulated only with the combination treatment in MDA-MB-231 (a more invasive cell line) cells even though eIF2-α phosphorylation is upregulated in samples treated with single drugs. eIF-4E, the mRNA cap-binding protein essential for the initiation of translation, has been found to contribute to malignancy by enabling translation of select mRNAs that encode proteins involved in growth, angiogenesis, survival and malignancy . Interestingly, ER stress signaling and eIF2-α phosphorylation have been linked to drug resistance and survival in occult dormant carcinoma cells . However, eIF2-α has never before been characterized specifically as a regulator of metastasis. Therefore, studies aimed at characterizing the involvement of eIF2 in metastasis, both in vivo and in vitro, are a natural continuation of these findings as are studies aimed at examining the potential of Nck1 inhibition as a therapy specific for metastatic breast cancer.
Combination therapies are especially useful in the treatment of many cancers, in part due to the ability of separate drugs to target multiple separate survival pathways upregulated in many cancer lineages . In these studies, we have used the concept of combination therapies to delineate the interaction between OSU-03012 and lapatinib. We showed that OSU-03012 and lapatinib synergized to induce cell death in both an ER positive and an ER negative breast cancer cell line suggesting that this therapeutic model may be effective against a variety of breast cancer phenotypes. We also demonstrated that eIF2-α phosphorylation is a central event in the synergistic cytotoxicity/cytostaticity induced by the combination therapy of OSU-03012 and lapatinib, and that this event is partially mediated by the protein phosphatase PP1/Nck/eIF2 complex.
These studies describe a novel mechanism of cytotoxicity/cytostaticity via Nck1-mediated eIF2-α phosphorylation for the combination of lapatinib and OSU-03012. We conclude that OSU-03012 and lapatinib act synergistically to induce cell death via the downregulation of Nck1/PP1 and the subsequent dissociation of this complex from eIF2-α. We also conclude that this dissociation likely leads to a PP1-mediated enhancement of eIF2-α phosphorylation at serine51, a marker for ER stress and a central event in the induction of cell death by OSU-03012/lapatinib. This work additionally identifies the Nck1/PP1/eIF2-α as a novel target for inhibition for future therapies.
We would like to acknowledge the laboratory of Dr. Louise Larose for their generous contribution of the GFPNck1 and GFPNck2 expression plasmids, and the laboratory of Dr. Paul Dent for their generous contribution of siRNA to ATF6 and IRE1α. This work was supported by grants from the Veteran’s Administration (Research Career Scientist Award to CEC BX001792), and from the National Institutes of Health (CA154314 (CEC), NH1C06-RR17393 (to Virginia Commonwealth University for renovation).
Services and products in support of the research project were generated by the VCU Massey Cancer Center Flow Cytometry Shared Resource, supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30 CA016059. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 9.Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, et al: Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009, 20 (6): 1026-1031. 10.1093/annonc/mdn759.CrossRefPubMedGoogle Scholar
- 11.Chen ST, Thomas S, Gaffney KJ, Louie SG, Petasis NA, Schonthal AH: Cytotoxic effects of celecoxib on raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leuk Res. 2010, 34 (2): 250-253. 10.1016/j.leukres.2009.09.028.CrossRefPubMedGoogle Scholar
- 12.Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH, et al: Targeting endoplasmic reticulum stress and akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res. 2008, 68 (8): 2820-2830. 10.1158/0008-5472.CAN-07-1336.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Muaddi H, Majumder M, Peidis P, Papadakis AI, Holcik M, Scheuner D, et al: Phosphorylation of eIF2α at Serine 51 Is an Important Determinant of Cell Survival and Adaptation to Glucose Deficiency. Mol Biol Cell. 2010, 21 (18): 3220-3231. 10.1091/mbc.E10-01-0023.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Teske BF, Wek SA, Bunpo P, Cundiff JK, McClintick JN, Anthony TG, et al: The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Mol Biol Cell. 2011, 22 (22): 4390-4405. 10.1091/mbc.E11-06-0510.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Sanz-Pamplona R, Aragüés R, Driouch K, Martín B, Oliva B, Gil M, et al: Expression of Endoplasmic Reticulum Stress Proteins Is a Candidate Marker of Brain Metastasis in both ErbB-2+ and ErbB-2− Primary Breast Tumors. Am J Pathol. 2011, 179 (2): 564-579. 10.1016/j.ajpath.2011.04.037.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.O’Loghlen A, Pérez-Morgado MI, Salinas M, Martín ME: Reversible inhibition of the protein phosphatase 1 by hydrogen peroxide: Potential regulation of eIF2α phosphorylation in differentiated PC12 cells. Arch Biochem Biophys. 2003, 417 (2): 194-202. 10.1016/S0003-9861(03)00368-0.CrossRefPubMedGoogle Scholar
- 39.Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA: Functional coupling of p38-induced Upregulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006, 66: 1702-1711. 10.1158/0008-5472.CAN-05-3092.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Sharma SV, Settleman J: Exploiting the balance between life and death: Targeted cancer therapy and “oncogenic shock” Biochem. Pharmacol. 2010, 80 (5): 666-673.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/256/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.